← Back to Search
Structures Of Purine Nucleosidase From Trypanosoma Brucei Bound To Isozyme-specific Trypanocidals And A Novel Metalorganic Inhibitor.
F. Giannese, M. Berg, P. Van der Veken, V. Castagna, P. Tornaghi, K. Augustyns, M. Degano
Published 2013 · Biology, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Sleeping sickness is a deadly disease that primarily affects sub-Saharan Africa and is caused by protozoan parasites of the Trypanosoma genus. Trypanosomes are purine auxotrophs and their uptake pathway has long been appreciated as an attractive target for drug design. Recently, one tight-binding competitive inhibitor of the trypanosomal purine-specific nucleoside hydrolase (IAGNH) showed remarkable trypanocidal activity in a murine model of infection. Here, the enzymatic characterization of T. brucei brucei IAGNH is presented, together with its high-resolution structures in the unliganded form and in complexes with different inhibitors, including the trypanocidal compound UAMC-00363. A description of the crucial contacts that account for the high-affinity inhibition of IAGNH by iminoribitol-based compounds is provided and the molecular mechanism underlying the conformational change necessary for enzymatic catalysis is identified. It is demonstrated for the first time that metalorganic complexes can compete for binding at the active site of nucleoside hydrolase enzymes, mimicking the positively charged transition state of the enzymatic reaction. Moreover, we show that divalent metal ions can act as noncompetitive IAGNH inhibitors, stabilizing a nonproductive conformation of the catalytic loop. These results open a path for rational improvement of the potency and the selectivity of existing compounds and suggest new scaffolds that may be used as blueprints for the design of novel antitrypanosomal compounds.
This paper references
Features and development of Coot
P. Emsley (2010)
Control and Surveillance of African Trypanosomiasis. Geneva: World Health Organization
Markell and Voge's medical parasitology
D. T. John (1999)
Inhibitors of the Purine Salvage Pathway: A Valuable Approach for Antiprotozoal Chemotherapy?
M. Berg (2010)
Coot: model-building tools for molecular graphics.
P. Emsley (2004)
Adenosine Kinase of T. b. rhodesiense Identified as the Putative Target of 4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl]morpholine Using Chemical Proteomics
S. Kuettel (2009)
Development of transition state analogues of purine nucleoside phosphorylase as anti-T-cell agents.
V. Schramm (2002)
Leaving group activation by aromatic stacking: an alternative to general acid catalysis.
W. Versées (2004)
Targeting large kinase active site with rigid, bulky octahedral ruthenium complexes.
J. Maksimoska (2008)
Uptake of purine bases and nucleosides in African trypanosomes.
D. M. James (1980)
Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda.
D. Legros (1999)
A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).
V. Gandhi (2005)
Guanosine-inosine-preferring nucleoside N-glycohydrolase from Crithidia fasciculata.
B. Estupiñán (1994)
Iminoribitol transition state analogue inhibitors of protozoan nucleoside hydrolases.
R. W. Miles (1999)
Energy landscapes associated with macromolecular conformational changes from endpoint structures.
A. Fornili (2010)
Copper(II) Ion and Nickel(II) Ion Complexes with 2-Amino-2-(hydroxymethyl)-1,3-propanediol. Reactions with Sodium Hydroxide
J. L. Hall (1962)
Trypanosomal nucleoside hydrolase. A novel mechanism from the structure with a transition-state inhibitor.
M. Degano (1998)
Overview of the CCP4 suite and current developments
M. Winn (2011)
M. Berg (2010)
Development of novel drugs for human African trypanosomiasis.
R. Brun (2011)
Structural basis for substrate specificity in group I nucleoside hydrolases.
E. Iovane (2008)
Crystal structure to 1.7 a of the Escherichia coli pyrimidine nucleoside hydrolase YeiK, a novel candidate for cancer gene therapy.
B. Giabbai (2004)
Biochemistry 38, 13147-13154
wARP: improvement and extension of crystallographic phases by weighted averaging of multiple-refined dummy atomic models.
A. Perrakis (1997)
Metal Ion/Buffer Interactions
B. E. Fischer (1979)
G.G. Stokes (1890)
Catalysis by nucleoside hydrolases.
W. Versées (2003)
Plasmodium falciparum Parasites Are Killed by a Transition State Analogue of Purine Nucleoside Phosphorylase in a Primate Animal Model
M. Cassera (2011)
N-Arylmethyl substituted iminoribitol derivatives as inhibitors of a purine specific nucleoside hydrolase.
A. Goeminne (2008)
The Genome Sequence of Trypanosoma brucei gambiense, Causative Agent of Chronic Human African Trypanosomiasis
A. Jackson (2010)
Transition-state complex of the purine-specific nucleoside hydrolase of T. vivax: enzyme conformational changes and implications for catalysis.
W. Versées (2006)
NUCLEOSIDE-PHOSPHORYLASE DEFICIENCY IN A CHILD WITH SEVERELY DEFECTIVE T-CELL IMMUNITY AND NORMAL B-CELL IMMUNITY
EloiseR. Giblett (1975)
Purine and pyrimidine transport in pathogenic protozoa: from biology to therapy.
H. D. de Koning (2005)
The interpretation of protein structures: estimation of static accessibility.
B. Lee (1971)
Metal Complexing by Tris Buffer
D. Allen (1967)
Inosine-uridine nucleoside hydrolase from Crithidia fasciculata. Genetic characterization, crystallization, and identification of histidine 241 as a catalytic site residue.
D. N. Gopaul (1996)
Crystal structures of T. vivax nucleoside hydrolase in complex with new potent and specific inhibitors.
W. Versées (2009)
The Genome of the African Trypanosome Trypanosoma brucei
M. Berriman (2005)
Enzymes of the human erythrocyte. II. Purine nucleoside phosphorylase; specific properties.
K. Tsuboi (1957)
W. Kabsch (2010)
Recent advances in identifying and validating drug targets in trypanosomes and leishmanias.
M. Barrett (1999)
Nucleoside hydrolase from Crithidia fasciculata. Metabolic role, purification, specificity, and kinetic mechanism.
D. W. Parkin (1991)
Structure and mechanism of the 6-oxopurine nucleosidase from Trypanosoma brucei brucei.
An Vandemeulebroucke (2010)
V. L. Schramm (2002)
On the treatment of negative intensity observations
S. French (1978)
Purine metabolism in Trypanosoma cruzi.
R. Berens (1981)
Isozyme-specific transition state inhibitors for the trypanosomal nucleoside hydrolases.
D. W. Parkin (1997)
REFMAC5 for the refinement of macromolecular crystal structures
G. Murshudov (2011)
Mechanistic Diagnoses of N-Ribohydrolases and Purine Nucleoside Phosphorylase
L. Mazzella (1996)
ARP/wARP and molecular replacement: the next generation
S. Cohen (2008)
Three-dimensional structure of the inosine-uridine nucleoside N-ribohydrolase from Crithidia fasciculata.
M. Degano (1996)
Biochemistry, 49, 8999–9010
Purine-specific Nucleoside N-Ribohydrolase from Trypanosoma brucei brucei
D. W. Parkin (1996)
Structure and function of a novel purine specific nucleoside hydrolase from Trypanosoma vivax.
W. Versées (2001)
Purine and pyrimidine metabolism in the Trypanosomatidae.
D. Hammond (1984)
Adenosine cycle in African trypanosomes.
P. O. Ogbunude (1985)
Correlation of the molecular electrostatic potential surface of an enzymatic transition state with novel transition-state inhibitors.
B. Horenstein (1993)
Biochemistry, 36, 3528–3534
V. L. Schramm (1997)
Crystal Structures of T. b. rhodesiense Adenosine Kinase Complexed with Inhibitor and Activator: Implications for Catalysis and Hyperactivation
S. Kuettel (2011)
MolProbity: all-atom structure validation for macromolecular crystallography
Vincent B. Chen (2010)
Molecular replacement with MOLREP.
A. Vagin (2010)
Evaluation of Nucleoside Hydrolase Inhibitors for Treatment of African Trypanosomiasis
M. Berg (2010)
Integration, scaling, space-group assignment and post-refinement
W. Kabsch (2010)
Adenosine Kinase Mediates High Affinity Adenosine Salvage in Trypanosoma brucei*
M. Vodnala (2008)
Efficient anisotropic refinement of macromolecular structures using FFT.
G. Murshudov (1999)
How to measure and predict the molar absorption coefficient of a protein
C. Pace (1995)
This paper is referenced by
The Potential of Secondary Metabolites from Plants as Drugs or Leads against Protozoan Neglected Diseases—Part III: In-Silico Molecular Docking Investigations
I. V. Ogungbe (2016)
Immucillins Impair Leishmania (L.) infantum chagasi and Leishmania (L.) amazonensis Multiplication In Vitro
E. Freitas (2015)
Computational insight into the broad substrate specificity of enzymes that process nucleic acids
S. Lenz (2018)
In Silico Investigation of Flavonoids as Potential Trypanosomal Nucleoside Hydrolase Inhibitors
C. Ha (2015)
Nucleoside Hydrolase NH 36: A Vital Enzyme for the Leishmania Genus in the Development of T-Cell Epitope Cross-Protective Vaccines
C. B. Palatnik-de-Sousa (2019)
Cloning and characterisation of the Equilibrative Nucleoside Transporter family of Trypanosoma cruzi: ultra-high affinity and selectivity to survive in the intracellular niche.
G. D. Campagnaro (2018)
In Silico Identification of New Targets for Diagnosis, Vaccine, and Drug Candidates against Trypanosoma cruzi
Rafael Obata Trevisan (2020)
Structural explanation for the tunable substrate specificity of an E. coli nucleoside hydrolase: insights from molecular dynamics simulations
Stefan A. P. Lenz (2018)
Design, synthesis and antitrypanosomal activity of heteroaryl-based 1,2,4-triazole and 1,3,4-oxadiazole derivatives.
M. S. Shaykoon (2020)